Hybridan Research: Sareum Holdings plc: Upping the Pace
There is a loss before tax reduced to £1.33m, compared to a loss of £2.5m (H123 to end Dec 2023) which included Phase 1a clinical trial costs.
236 Views
Sareum Holdings — New fund-raise and licence signal active 2025
Sareum Holdings has announced the acquisition of the licence for SRA737, a checkpoint kinase 1 (CHK1) inhibitor, in which the company had...
358 Views
Sareum Holdings PLC - Opportunistic Opportunity 13 March 2025
Sareum has now acquired this licence, and the economic terms have been renegotiated, so Sareum will receive a net 63.5% of all future revenues, up...
321 Views
Smarttech247 Group PLC - Hybridan Small Cap Feast: 29/05/2025
Our daily digest of news from UK Small Caps 29th May 2025 @HybridanLLP * A corporate client of...
315 Views
Smarttech247 Group PLC - Hybridan Small Cap Feast: 28/04/2025
Revenue on a continuing basis is up by 15.4% to £60.4m (2023: £52.3m) and operating profit before non-recurring costs improved to £2.0m (2023: £0.3m).
272 Views